Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
223
resultados
Última actualización
18/08/2026 [06:57:00]
Resultados 25 a 50 de 223
Resumen de: GB2703647A
A system capable of tracking medicine comprising a locating device attached to the item to be tracked such as an insulin pen. The system may also comprise a smart phone app for connecting with the locating device and receiving the location information, a purpose built plastic container that holds the tracking components and attaches to the device to be tracked, and a light or a means of making sound within the tracking device to alert a user to the location of the item. Figure 1
Resumen de: US2025108160A1
0000 Systems and methods are provided for managing communication with a user of an insulin pump system for improving insulin pump operation and/or a user experience relating to the insulin delivery system. The insulin pump system may analyze data from a user of a certain insulin pump and/or data from users of different insulin pumps and determine patterns relating to such use and indicative of certain user experiences. Based on the detected patterns and/or events associated with the patterns or user experiences, user messages may be proactively sent a user device and/or smart device of the user. The user messages may be designed to improve a user experience and/or prevent a negative outcome. For example, a message may be a training video, may include a reminder to adjust pump operation for a certain activity, and/or may include an alert to reorder more supplies.
Resumen de: EP4529835A1
0001 A method of non-invasive determination of the blood glucose concentration in the patient's tissue based on a radio noise signal received using an antenna brought close to the patient's skin according to the invention is distinguished by that the radio noise signal is received using a total power radiometer and additionally the method includes the following steps: a step of obtaining transformation coefficients, a step of measuring the temperature of the tissue surface, a step of measuring the temperatures of the active elements of the receiving chain of the radiometer, a step of measuring the currents consumed by the active elements of the receiving chain of the radiometer, a step of measuring the power of the radio noise signal originating from the tissue, and a step of determining the blood glucose concentration based on the aforementioned values. The invention also relates to a computer program, a radiometer, and a device for determining glucose concentration.
Resumen de: US2025111918A1
0000 Systems and methods are provided including insulin pump systems for determining certain information about a user of a wearable insulin pump based on naturally spoken user data by applying the user data to a large language model (LLM) or other machine learning model to parse the user data into categories. For example, certain rules and/or constraints may be provided to the LLM and may cause the LLM or machine learning model to parse the user data into defined categories that may be used for updating a user record. Categories may include food consumption, activities, sleep, and/or pump operation information, for example. Additional data may be determined from the parsed data such as caloric information, exercise duration, sleep information and the like. The parsed categorized data and/or additional data may be used to adjust operation of the insulin delivery pump.
Resumen de: US2025099674A1
Disclosed herein are systems and methods for transitioning between different CGM sensors in an infusion pump system with no loss in continuity of glucose levels between different sensor for use in closed loop diabetes therapy. Notifications can be provided to the user when a subsequent CGM sensor ought to be inserted, based on specific mechanics of the previous CGM sensor and of the anticipated subsequent CGM sensor. The system can further provide a notification when the subsequent CGM sensor is activated following the warm up period and capable of transmitting CGM data for use in the system and can prompt the user to or automatically transition the system from communicating with the previous sensor for CGM data to the subsequent sensor. Following the transition, the system may also notify the user that the previous CGM sensor can be removed from the user's body.
Resumen de: USRE50976E
A wearable diagnostic device worn on a user's body that can provide various types of health-related information to the user is described. The wearable diagnostic device can provide real-time, non-invasive, accurate, and continuous data regarding a user's heart rate, hemoglobin level, body temperature, oxygen level, glucose level, and blood pressure. In some implementations, the wearable diagnostic device may also provide electrocardiogram (EKG) data or detection of Parkinson's symptoms, such as the involuntary movement of a user's hand. A user may configure the wearable diagnostic device to provide information on one, multiple, or all of the health-related information noted above.
Resumen de: WO2026157245A1
Disclosed in the present application are a method for evaluating blood glucose, a user interface, and a related apparatus. The method comprises: obtaining a PPG signal of a user in a time period; displaying the acquisition progress of the PPG signal in the process of obtaining the PPG signal; and then determining a blood glucose result of the user on the basis of the PPG signal, and displaying the blood glucose result. When the acquisition progress of the PPG signal is determined, the method can divide the PPG signal into PPG signal intervals in a plurality of windows by using a specified duration as a window size, and determine a ratio of the number of valid PPG signal intervals in the plurality of PPG signal intervals to a preset number as the acquisition progress of the PPG signal. It can be seen that the method determines the acquisition progress of the PPG signal according to the number of valid PPG signal intervals divided from the PPG signal, such that the acquisition progress of the PPG signal better aligns with the user's actual perception of the signal acquisition progress during the course of PPG signal acquisition.
Resumen de: AU2024410022A1
A continuous analyte monitoring system includes analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller is coupled to the analyte sensors and configured evaluate first samples of outputs of a first analyte sensor and second samples of outputs of a second analyte sensor to determine whether the first samples and the second samples indicate compression of the tissue. The controller compensates for the compression of the tissue with respect to the first samples. A force sensor may be used and may be positioned between a circuit board and a housing, the circuit board supported by supports providing preloading of the force sensor. A force deflector may be used to direct loads away from tissue holding the analyte sensors. A housing may have a flexible lower surface to reduce loading of the tissue.
Resumen de: WO2026157932A1
Provided is a deuterium-labeled probe for diagnosing and monitoring AD using a magnetic resonance deuterium imaging application technology. The present invention provides use of a deuterium-labeled molecular probe or a composition comprising a deuterium-labeled molecular probe in the preparation of a kit or system, wherein the kit or system is used for accurately diagnosing Alzheimer's disease or dynamically monitoring progression of Alzheimer's disease in a subject, the deuterium-labeled molecular probe is selected from deuterium-labeled glucose, a deuterium-labeled acetate, or a deuterium-labeled amino acid, and the Alzheimer's disease is early-stage, intermediate-stage, or late-stage Alzheimer's disease. The present invention achieves early and accurate detection of Alzheimer's disease.
Resumen de: WO2026157189A1
The present invention relates to a cartilage organoid constructed on the basis of a DNA-fibroin hybrid hydrogel sustained-release system, a method for preparing same, and use thereof. The DNA-fibroin hybrid hydrogel sustained-release system is a hydrogel system obtained after a pre-mixed solution of the DNA-fibroin hybrid hydrogel sustained-release system is printed by means of a digital light processing system, wherein the pre-mixed solution of the DNA-fibroin hybrid hydrogel sustained-release system comprises DNA, fibroin, an acrylated RGD peptide, an acrylated polyethylene glycol NHS ester, glucosamine, TD-198946, and lithium 2,4,6-trimethylbenzoylphosphate. Compared to the prior art, the glucosamine and TD-198946 introduced into the DNA-fibroin hybrid hydrogel sustained-release system of the present invention can significantly improve the efficiency of promoting the chondrogenic differentiation of bone marrow mesenchymal stem cells. The present invention can be transplanted as a cartilage graft to a cartilage defect site to promote cartilage regeneration and repair.
Resumen de: US20260215704A1
A medical device includes a medical tool such as an inserter for a continuous glucose monitor. Typically a housing of the medical tool has an indicator area with an indicator field that irreversibly changes its appearance at a predetermined environmental parameter condition. In exemplary embodiments, the predetermined environmental parameter condition can be a predetermined humidity, a change in a predetermined humidity condition, a predetermined temperature or a predetermined temperature change. A controller is connected to the medical tool and is configured to determine the appearance of the indicator field at the time of use of the medical tool and is also configured to control the function of the medical tool based upon the determined appearance of the indicator field.
Resumen de: US20260219259A1
A method to rapidly and inexpensively quantify human insulin secreted from human cells. This method for quantifying insulin secretion capacity in a human cell involves culturing a recombinant cell and measuring an amount of a secreted fused C-peptide. The recombinant cell is prepared by replacing an insulin gene in the genome of a human cultured cell line with a gene which expresses a fused C-peptide having a detectable tag peptide inserted in a C-peptide chain in a human proinsulin molecule.
Resumen de: US20260215703A1
0000 Provided is a sensor applicator assembly for a blood glucose monitoring, comprising an applicator, and a body attachment unit disposed inside the applicator and comprising a housing including an upper frame and a lower frame. The lower frame comprises a recess portion formed throughout an entire section along a perimeter direction.
Resumen de: US20260215741A1
Methods, devices, systems, and kits are provided that buffer the time spaced glucose signals in a memory, and when a request for real time glucose level information is detected, transmit the buffered glucose signals and real time monitored glucose level information to a remotely located device, process a subset of the received glucose signals to identify a predetermined number of consecutive glucose data points indicating an adverse condition such as an impending hypoglycemic condition, confirm the adverse condition based on comparison of the predetermined number of consecutive glucose data points to a stored glucose data profile associated with the adverse condition, where confirming the adverse condition includes generating a notification signal when the impending hypoglycemic condition is confirmed, and activate a radio frequency (RF) communication module to wirelessly transmit the generated notification signal to the remotely located device only when the notification signal is generated.
Resumen de: US20260216283A1
0000 Chronic wounds are characterized by a persistent, hyper-inflammatory environment that prevents progression to regenerative wound closure. Such chronic wounds are especially common in diabetic patients, often requiring distal limb amputation, but occur in non-diabetic, elderly patients as well. Induced expression of HoxA3, a member of the Homeobox family of body patterning and master regulatory transcription factors, has been shown to accelerate wound closure in diabetic mice when applied topically as a plasmid encased in a hydrogel. We now provide independent replication of those foundational in vivo diabetic wound closure studies and expand upon them with minimal dose threshold estimation. Furthermore, we observed similarities in natural wound healing velocity between aged non-diabetic mice and young diabetic mice, which provided motivation to test topical HoxA3 plasmid in aged non-diabetic mice, where we again observed accelerated wound healing. We did not observe any gross adverse effects macroscopically or via local histology in these short studies. Whether as a plasmid or future alternative modality, topical HoxA3 is an attractive translational candidate for chronic wounds.
Resumen de: US20260216060A1
0000 The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with needle height dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa~7.5) that quickly and spontaneously crosslinks upon mixing of the polymer solutions by auto-oxidation of catechol groups and reversible interactions between AFBA and catechol functional groups in the absence of any chemical crosslinking agent. The DA and AFBA content were selected for conjugation into the backbone of the HA polymer for the desired hormone delivery profile. The patch provides high drug loading capacity for long-term drug delivery application. The crosslinking mechanism for microneedle fabrication is biocompatible and beneficial for sustaining hormone drug stability and bioactivity as it does not require harsh crosslinking conditions. Facile pH adjustment of the matrix hydrogel can be easily casted into a microneedle patch without multistep processes that conventional patch polymerization requires. The present matrix microneedle patch demonstrates sufficient skin penetration, rapid swelling in interstitial media, high drug loading capacity and effective hypo/hyperglycemia prevention by the automated hypo/hyperglycemia-triggered delivery of hormones through the skin.
Resumen de: WO2026156536A1
The present application discloses a video product for inducing a cognitive impairment behavior, and a storage medium. The video product comprises a plurality of video units, each video unit comprises a plurality of video clips, and each video clip displays a target element, a prompt element and/or an interference element. In the present application, by means of different elements in the video clips, a subject is induced to make behavioral responses, thereby measuring multiple types of cognitive abilities of the subject including visuospatial ability, memory ability, language ability, calculation ability, complex attention ability, smooth pursuit ability, execution ability, social cognition ability, emotional response ability, incongruity detection ability, and narrow vision ability, thus achieving screening, diagnosis, treatment, and efficacy evaluation of cognitive impairment caused by Alzheimer's disease, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, diabetes, and the like. By using the video product of the present invention, the processes of the described screening, diagnosis, treatment, and efficacy evaluation are more objective, and the results have higher reliability and consistency.
Resumen de: US20260215686A1
0000 Various embodiments of systems, devices and methods for improving the accuracy of an analyte sensor and for detecting sensor fault conditions are disclosed. According to some embodiments, these systems, devices, and methods can utilize a first data collected by a glucose sensor and a second data collected by a secondary sensing element. In some embodiments, the secondary sensing element can be one of a lactate sensing element, a ketone sensing element, or a heart rate monitor, among others.
Resumen de: WO2026160421A1
The present disclosure provides cells that exhibit competitiveness with respect to cancer cells without being starved and exhausted even in a glucose depleted environment. More specifically, the present disclosure provides cells that are effective in metabolic (for example, low glucose, high lactic acid, and high fatty acid environments) and immunological tumor environments (chemokine profiles that induce immunosuppressive immune cells, expression of checkpoint molecules, and inhibitory cell infiltration that negatively regulates antitumor immune responses, the inhibitory cells being typified by inhibitory cytokines and Treg cells) in which infiltration by normal T-cells or conventional genetically modified cells are inhibited, and in which, in addition, even if infiltration occurs, said cells cannot exhibit long-term effector functions due to starvation and exhaustion. The present disclosure also provides T-cells having an effector function, wherein the T-cells are modified so as to express Foxp3 (including mutants and partial deletions), and/or have an enhanced expression of Foxp3.
Resumen de: AU2026205438A1
STEM CELL DERIVED ISLET DIFFERENTIATION Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells. STEM CELL DERIVED ISLET DIFFERENTIATION ul u l
Resumen de: EP4782536A1
Provided are a γδT cell targeting PD-L1, and a preparation method therefor and the use thereof. By means of unnatural sugar metabolic labeling, the γδT cell is modified with a first active group, and then same and a PD-L1 targeting group modified with a second active group are subjected to a bioorthogonal reaction, thereby obtaining the γδT cell targeting PD-L1. The γδT cell targeting PD-L1 has a targeted and selective killing effect on PD-L1-positive tumor cells; has the advantages of a short preparation cycle, suitability for large-scale production, uniform and stable quality, etc.; and has good application prospects.
Resumen de: EP4782547A1
The present invention provides a method for preparation of fully 13C isotopically labeled biomolecules or biomolecules having a predetermined 13C isotopic labeling by biosynthesis in a mammalian cell line, which comprises the following steps:a) providing a mammalian cell line capable of growing in serum-free media;b) culturing the cell line obtained in step b) in a serum-free medium containing: fully 13C isotopically labeled amino acids or 13C isotopically labeled amino acids, fully 13C isotopically labeled glucose and/or fully 13C isotopically labeled galactose, or 13C isotopically labeled glucose and/or 13C isotopically labeled galactose, fully 13C isotopically labeled choline or 13C isotopically labeled choline, vitamins, distilled water, insulin, transferrin, sodium selenite, and inorganic salts wherein when the inorganic salt contains carbon, it is preferably fully 13C isotopically labeled;c) obtaining 13C isotopically labeled biomolecules from the cells or medium after the cultivation of step b).The resulting biomolecules and their mixtures are suitable for use as internal standards in metabolomics and fluxonics, as well as in biotechnological research as standards or markers.
Resumen de: US2021008122A1
0001 The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.
Resumen de: US2025090754A1
0000 Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G′(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G′(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
Nº publicación: EP4780327A2 29/07/2026
Solicitante:
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc.
Resumen de: CN121843651A
A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure a ketone level in a patient's bodily fluid. The application is configured to display at least one of (1) a current ketone level, and an indicator of a current ketone trend, (2) a ketone trend graph, and (3) a total amount of time for which the ketone level is above at least one predetermined threshold level. The application is further configured to determine whether the current ketone level is above the at least one predetermined threshold level, and output an alert in response to determining that the current ketone level is above the at least one predetermined threshold level, where the alert is periodically output when the current ketone level is above the at least one predetermined threshold level.
BOPI
Sede Electrónica
